Drug news
Stivarga filed at EMA for GIST
Bayer HealthCare has submitted an application for marketing authorization to the European Medicines Agency (EMA) for the oral multi-kinase inhibitor, Stivarga (regorafenib), for the treatment of patients with Gastrointestinal Stromal Tumours (GlST) who have been previously treated with two tyrosine kinase inhibitors. The EMA filing follows the EU approval of regorafenib (Stivarga) for use in metastatic Colorectal Cancer in August 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.